Personalized treatment system and method for sleep disorder of dementia patient

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a personalized treatment system and method for sleep disorder of a dementia patient. According to the medicine prepared by taking dihydromyricetin as a raw material, the ATP supply of the brain can be increased, the Gephyr protein level can be increased, and the function of brain inhibitory neurons (GAMA aminobutyric acid) can be improved; the compound can effectively improve the sleep disorder at night of a dementia patient, especially the dysphoria at night and excitement accompanied by the dysphoria at night.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a personalized treatment system and method for sleep disorders in dementia patients. Background Art

[0002] 70% of various dementias such as Alzheimer's disease, post-stroke dementia, Parkinson's dementia, etc. are accompanied by sleep disorders. Common manifestations of sleep disorders include nocturnal restlessness, overexcitement, sunset agitation, etc. There is an imbalance between inhibitory neurons and excitatory neurons in the brains of dementia patients, and the sleep-wake rhythm is disrupted. The current methods available on the market for the above scenarios are to use antipsychotic drugs or anti-insomnia, anti-anxiety and anti-depression drugs. However, antipsychotic drugs can cause significant cognitive impairment, damage to higher brain nerve functions, and motor function impairment; in addition, anti-insomnia and anti-anxiety and anti-depression drugs often have significant adverse reactions such as drowsiness, fatigue, incoordination of limb movements, poor memory, sexual dysfunction, etc., and are dependent and tolerant. Summary of the invention

[0003] In order to address the deficiencies of the above-mentioned prior art, the present invention provides an application of dihydromyricetin in treating dementia with sleep disorders, with the purpose of solving the technical problems in the prior art that, for dementia with sleep disorders, anti-schizophrenia drugs or anti-insomnia, anti-anxiety and depression drugs are used to treat the disorder, which causes users to suffer from adverse reactions such as drowsiness, fatigue, uncoordinated limb movements, poor memory, sexual dysfunction, etc., and has dependence and tolerance, and is not safe enough.

[0004] The present invention provides a personalized treatment system and method for sleep disorders in patients with dementia, and the specific technical scheme is as follows:

[0005] A personalized treatment system and method for sleep disorders in patients with dementia, using dihydromyricetin as one of the active ingredients or the only active ingredient for preparing a drug for treating dementia with sleep disorders.

[0006] In certain embodiments, the dihydromyricetin is a crude dihydromyricetin or a dihydromyricetin monomer extracted from a dihydromyricetin-containing plant.

[0007] Furthermore, dihydromyricetin is a crude dihydromyricetin or a dihydromyricetin monomer extracted from Rhizoma Cibotii.

[0008] In certain embodiments, dihydromyricetin is synthesized by chemical methods.

[0009] In certain embodiments, the dosage form of the food or drug for treating dementia with sleep disorders is oral liquid, granules, capsules, tablets, effervescent tablets, syrups, pills, pastes, soft capsules, ointments, emulsions, powders, sustained-release agents, controlled-release agents, targeted preparations, powder injections, water injections, injections, nebulizers, microemulsions, gels, and nano preparations.

[0010] The present invention has the following beneficial effects: Dihydromyricetin (DHM), the structural formula of which is as follows Figure 1 As shown, it is a flavonoid compound. In addition to the general properties of flavonoid compounds, it also has the functions of relieving alcohol poisoning, preventing alcoholic liver and fatty liver, inhibiting liver cell deterioration, and reducing inflammation. It has great medicinal value. Existing research on dihydromyricetin mainly focuses on its biological activities such as antioxidant and anti-inflammatory.

[0011] The drug prepared by using dihydromyricetin as raw material can increase brain ATP supply, increase Gephyrin protein level, and improve the function of brain inhibitory neurons (GAMA aminobutyric acid); the compound can effectively improve the nocturnal sleep disorders of dementia patients, especially those accompanied by nocturnal restlessness and excitement. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 is the molecular structural formula of dihydromyricetin of the present invention;

[0013] Figure 2 This is a process flow chart of the extraction of dihydromyricetin in Example 1 of the present invention;

[0014] Figure 3 This is a comparison diagram of the effect of DHM on the level of Gephyrin protein in the brain of AD model mice in Example 1 of the present invention;

[0015] Figure 4 This is a comparison diagram of the effects of DHM on the cognitive ability of AD model animals in Example 2 of the present invention;

[0016] Figure 5 This is a comparison chart of sleep time before and after taking Example 3 of the present invention. DETAILED DESCRIPTION

[0017] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the following is a detailed description of the present invention in conjunction with the accompanying drawings. Figure 1-5 , the present invention is further described in detail.

[0018] Example 1

[0019] The dihydromyricetin in this embodiment is extracted from Rhizoma Cibotii (Rhizoma Cibotii). Figure 2As shown, 50% of dihydromyricetin was obtained by filtration and drying, and 98% of dihydromyricetin was obtained by recrystallization. Animal experiments were performed using DHM extracted by the above method.

[0020] Sixteen 20-month-old transgenic AD model mice (TG-SwDI) and eight non-transgenic mice (wild-type Wt) of the same age were selected as controls and divided into three groups: control group, AD model group, and AD treatment group (DHM 2mg / kg / day), which were orally administered (mixed in feed) for 3 consecutive months. The levels of Gephyrin protein in the brain of each group were detected at 1.5 months and 3 months. Figure 3 As shown, dihydromyricetin (DHM) increases the level of Gephyrin protein in the brain of Alzheimer's disease (AD).

[0021] Example 2

[0022] In this embodiment, dihydromyricetin is synthesized by chemical methods. Animal experiments are performed using DHM extracted by the above chemical synthesis method.

[0023] Sixteen 20-month-old transgenic AD model mice (TG-SwDI) and eight non-transgenic mice of the same age (wild-type Wt) were selected as controls and divided into four groups: control group, control + DHM group (2 mg / kg / day), AD model group, and AD treatment group (DHM2 mg / kg / day). They were orally administered (mixed in feed) for 3 consecutive months. The effect of DHM on the cognitive ability of AD model animals was observed, and the novel object recognition rate (ORI) and novel content recognition rate (RI) were used as evaluation indicators. Figure 4 As shown, DHM effectively improved the cognitive ability of AD model animals.

[0024] Example 3

[0025] 30 volunteers with sleep disorders (including early awakening, difficulty falling asleep, fragmented sleep, etc.) aged 30-70 years old, both male and female, were selected and used the drug provided in this embodiment which uses dihydromyricetin as one of the active ingredients. The drug provided in this embodiment is a solid beverage preparation (solid powder), and the method of use is to take it with warm water. Take 100 mg of DHM each time, 1-2 times a day, continue to use for 4 weeks, and observe the sleep time. The sleep time before taking this embodiment is counted, and the sleep time after taking it is also counted. Figure 5 As shown, after taking the medicine provided in this example, the volunteers' sleep time was greatly extended, effectively optimizing their sleep quality.

[0026] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. The present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by technicians in this technical field within the essential scope of the present invention should also fall within the protection scope of the present invention.

Claims

1. A personalized treatment system and method for sleep disorders in patients with dementia, characterized in that: Dihydromyricetin will be used as the active ingredient.

2. One of the ingredients or the only active ingredient is used to prepare a drug for treating dementia with sleep disorders.

3. A personalized treatment system and method for sleep disorders in patients with dementia according to claim 1, characterized in that: Dihydromyricetin is a crude dihydromyricetin product or a dihydromyricetin monomer extracted from plants containing dihydromyricetin.

4. A personalized treatment system and method for sleep disorders in dementia patients according to claim 2, characterized in that: Dihydromyricetin is a crude dihydromyricetin or a dihydromyricetin monomer extracted from Raspberry.

5. A personalized treatment system and method for sleep disorders in dementia patients according to claim 1, characterized in that: Dihydromyricetin is synthesized by chemical methods.

6. A personalized treatment system and method for sleep disorders in dementia patients according to claim 1, characterized in that: The food or drug preparations for treating dementia with sleep disorders are in the form of oral liquid, granules, capsules, tablets, effervescent tablets, syrups, pills, pastes, soft capsules, ointments, emulsions, powders, sustained-release agents, controlled-release agents, targeted preparations, powder injections, water injections, injections, atomizers, microemulsions, gels, and nano preparations.

Images